<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26038755</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2222-1751</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo.</ArticleTitle><Pagination><StartPage>e62</StartPage><MedlinePgn>e62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emi.2014.60</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) causes severe central nervous system infections, leading to cardiopulmonary complications and death in young children. There is an urgent unmet medical need for new pharmaceutical agents to control EV71 infections. Using a multidisciplinary approach, we found that the approved pediatric antiparasitic drug suramin blocked EV71 infectivity by a novel mechanism of action that involves binding of the naphtalentrisulonic acid group of suramin to the viral capsid. Moreover, we demonstrate that when suramin is used in vivo at doses equivalent to or lower than the highest dose already used in humans, it significantly decreased mortality in mice challenged with a lethal dose of EV71 and peak viral load in adult rhesus monkeys. Thus, suramin inhibits EV71 infection by neutralizing virus particles prior to cell attachment. Consequently, these findings identify suramin as a clinical candidate for further development as a therapeutic or prophylactic treatment for severe EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Peijun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai , Chinese Academy of Sciences, Shanghai 200031, China ; Universit&#xe9; Paris Diderot, Sorbonne Paris Cit&#xe9;, Cellule Pasteur , 75013, Paris, France ; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, U1108 &amp; Viral Pathogenesis Unit, Department of Virology, Institut Pasteur , 75724 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai , Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailly</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai , Chinese Academy of Sciences, Shanghai 200031, China ; Institute for Glycomics, Gold Coast Campus, Griffith University , 4222 Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai , Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Children's Hospital of Fudan University , Shanghai 201102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xinsheng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Lead Compound Research, WuXi AppTec, Co., Ltd, Shanghai 200131, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Lead Compound Research, WuXi AppTec, Co., Ltd, Shanghai 200131, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Science , Kunming 650118, Yunnan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillon</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Glycomics, Gold Coast Campus, Griffith University , 4222 Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenzana-Seisdedos</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, U1108 &amp; Viral Pathogenesis Unit, Department of Virology, Institut Pasteur , 75724 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchy</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Virology Unit, Institut Pasteur in Cambodia , 12201 Phnom Penh, Cambodia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Lead Compound Research, WuXi AppTec, Co., Ltd, Shanghai 200131, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Itzstein</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Glycomics, Gold Coast Campus, Griffith University , 4222 Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qihan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Science , Kunming 650118, Yunnan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmeyer</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai , Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-viral</Keyword><Keyword MajorTopicYN="N">drug discovery</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">hand, foot and mouth disease</Keyword><Keyword MajorTopicYN="N">suramin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26038755</ArticleId><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="doi">10.1038/emi.2014.60</ArticleId><ArticleId IdType="pii">emi201460</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther. 2009;7:735&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Hand, foot and mouth disease (HFMD) WHO: Manila; 2013. Available at http://www.wpro.who.int/emerging_diseases/HFMD/en/.</Citation></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol. 2009;47:2351&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, Schuffenecker I, Henquell C, et al. Phylogenetic evidence for a recent spread of two populations of human enterovirus 71 in European countries. J Gen Virol. 2010;91:2263&#x2013;2277.</Citation><ArticleIdList><ArticleId IdType="pubmed">20505012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, Pu D, Mo X, et al. Children of rural-to-urban migrant workers in China are at a higher risk of contracting severe hand, foot and mouth disease and EV71 infection: a hospital-based study. Emerg Microbes Infect. 2013;2:e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826070</ArticleId><ArticleId IdType="pubmed">26038441</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud CC, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014;14:308&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, El Khatib NF, Tu S, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol. 2012;53:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessaud M, Razafindratsimandresy R, Nougair&#xe8;de A, et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human Enterovirus 71 isolates reveal a wide genetic diversity. PLoS ONE. 2014;9:e90624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944068</ArticleId><ArticleId IdType="pubmed">24598878</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanh TH, Sabanathan S, Thanh TT, et al. Enterovirus 71-associated hand, foot, and mouth disease, Southern Vietnam, 2011. Emerg Infect Dis. 2012;18:2002&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3557876</ArticleId><ArticleId IdType="pubmed">23194699</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol. 2013;87:3335&#x2013;3347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol. 2013;87:611&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N, Cong H, Tian H, et al. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol. 2014;88:5816&#x2013;5833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019121</ArticleId><ArticleId IdType="pubmed">24623428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, Rossmann MG. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci USA. 2013;110:5463&#x2013;5467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>de Palma AM, Vliegen I, de Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev. 2008;28:823&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Song Z, Qin B, et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res. 2013;97:264&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Qi J, Chen Z, et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011;85:10319&#x2013;10331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhou F, Gu B, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157:669&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar HR, Poh CL, Fecondo J, Grollo L. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res. 2012;169:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorke W. The treatment of Kala-Azar by &#x201c;Bayer 205&#x201d;. Br Med J. 1923;1:370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2316014</ArticleId><ArticleId IdType="pubmed">20771033</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust SN, Woodrow CJ, Patel S, et al. Sleeping sickness in brothers in london. Pediatr Infect Dis J. 2004;23:879&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15361733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam ET, Au JL, Otterson GA, et al. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;66:1019&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919610</ArticleId><ArticleId IdType="pubmed">20107799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentsch KD, Hunsmann G, Hartmann H, Nickel P. Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. J Gen Virol. 1987;68:2183&#x2013;2192.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440983</ArticleId></ArticleIdList></Reference><Reference><Citation>Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. Suramin prevents duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 1993;37:1539&#x2013;1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188009</ArticleId><ArticleId IdType="pubmed">8363388</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Liu CF, Yan L, et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J. 2012;9:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Yang Y, Xu Y, Ma C, Qin C, Zhang L. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J. 2011;8:483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212826</ArticleId><ArticleId IdType="pubmed">22029605</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cui W, Liu L, et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest. 2011;91:1337&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555996</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Wang J, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One. 2013;8:e54451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Haselhorst T, Garcia JM, Islam T, et al. Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. Angew Chem Int Ed Engl. 2008;47:1910&#x2013;1912.</Citation><ArticleIdList><ArticleId IdType="pubmed">18232036</ArticleId></ArticleIdList></Reference><Reference><Citation>Haselhorst T, Fleming FE, Dyason JC, et al. Sialic acid dependence in rotavirus host cell invasion. Nat Chem Biol. 2009;5:91&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19109595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Iwasaki T, Ami Y, et al. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol. 2004;85:2981&#x2013;2989.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448361</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhao H, Zhang Y, et al. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology. 2011;412:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">21262515</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanchieri C, Butler AS, Knutsen A. Addressing the barriers to pediatric drug development: workshop summary. Washington, DC: The National Academies Press; 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">20669414</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong CR, Sullivan DJ., Jr New uses for old drugs. Nature. 2007;448:645&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">17687303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc. 2011;86:561&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104918</ArticleId><ArticleId IdType="pubmed">21628620</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaw M, Panosian CB. Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev. 1995;8:427&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC174634</ArticleId><ArticleId IdType="pubmed">7553575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin's development: what did we learn. Invest New Drugs. 2002;20:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">12099581</ArticleId></ArticleIdList></Reference><Reference><Citation>Scher HI, Jodrell DI, Iversen JM, et al. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 1992;52:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">1727387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden CJ, Figg WD, Dawson NA, et al. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol. 1996;39:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustberg MB, Pant S, Ruppert AS, et al. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012;70:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466596</ArticleId><ArticleId IdType="pubmed">22729159</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Shimizu H, Ami Y, et al. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol. 2002;67:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11992581</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmeyer R. Virus attachment and entry offer numerous targets for antiviral therapy. Curr Pharm Des. 2004;10:3701&#x2013;3712.</Citation><ArticleIdList><ArticleId IdType="pubmed">15579065</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercauteren K, Leroux-Roels G, Meuleman P. Blocking HCV entry as potential antiviral therapy. Future Virol. 2012;7:547&#x2013;561.</Citation></Reference><Reference><Citation>Curreli F, Choudhury S, Pyatkin I, et al. Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem. 2012;55:4764&#x2013;4775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372086</ArticleId><ArticleId IdType="pubmed">22524483</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster AD. Pleconaril&#x2014;an advance in the treatment of enteroviral infection in immuno-compromised patients. J Clin Virol. 2005;32:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108213</ArticleId><ArticleId IdType="pubmed">15571999</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89:2518&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitlinger MA, Derendorf H, Mouton JW, et al. Protein binding: do we ever learn. Antimicrob Agents Chemother. 2011;55:3067&#x2013;3074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122431</ArticleId><ArticleId IdType="pubmed">21537013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>